Phase 2 Alzheimer's Disease Trial, Recruiting NCT06467539 Sponsor: Chang Gung Memorial Hospital Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 2 Alzheimer's Disease Trial, Recruiting

NCT06467539
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Alzheimer's disease or mild cognitive impairment
  • People whose score on a standard memory and thinking test (called the MMSE) falls between 10 and 26
  • People whose level of dementia-related daily functioning has been rated as 0.5 (very mild) or 1 (mild) on a standard assessment scale (called the CDR)

Who may not be able to join:

  • People who score above 4 on a scale used to assess whether memory problems may be related to reduced blood flow in the brain (called the Hachinski Ischemic Score)
  • People who have a history of substance abuse or dependence
  • People who have Parkinson's disease, epilepsy, or dementia that includes symptoms such as hallucinations or delusions
  • People who have been diagnosed with major depressive disorder
  • People who have serious physical health conditions
  • People who have severe difficulty seeing or hearing

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
19 June 2024
Est. completion
1 May 2027

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov